Prostate cancer vaccine - Northwest Biotherapeutics

Drug Profile

Prostate cancer vaccine - Northwest Biotherapeutics

Alternative Names: CaPVax; DC1/HRPC; DCVax-Prostate

Latest Information Update: 08 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwest Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Suspended Prostate cancer

Most Recent Events

  • 08 Oct 2014 Phase-III development is still suspended
  • 04 Feb 2013 Prostate cancer vaccine - Northwest Biotherapeutics is available for licensing.
  • 04 Nov 2010 Northwest Biotherapeutics receives a Qualified Therapeutic Discovery Project grant from the US Government for DCVax® development in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top